The historical rank and industry rank for Jubilant Pharmova's FCF Margin % or its related term are showing as below:
BOM:530019'
s FCF Margin % Range Over the Past 10 Years
Min: -2.7 Med: 4.55 Max: 21.07
Current: -2.7
During the past 13 years, the highest FCF Margin % of Jubilant Pharmova was 21.07%. The lowest was -2.70%. And the median was 4.55%.
BOM:530019's FCF Margin % is ranked worse than 63.99% of 958
companies
in the Drug Manufacturers industry
Industry Median: 2.445
vs BOM:530019: -2.70
Jubilant Pharmova FCF Margin % Related Terms
Jubilant Pharmova FCF Margin % Historical Data
* Premium members only.
The historical data trend for Jubilant Pharmova's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Jubilant Pharmova's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jubilant Pharmova FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Jubilant Pharmova's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Jubilant Pharmova's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jubilant Pharmova (BOM:530019) has a FCF Margin % of 0.00% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Jubilant Pharmova and its competitors. According to the industry distribution chart, Jubilant Pharmova ranks #613 out of 958 companies in the Drug Manufacturers industry, placing it in the top 64%.
Is Jubilant Pharmova's FCF Margin % too high?
Jubilant Pharmova's current FCF Margin % is 0.00%. Based on the distribution chart, Jubilant Pharmova ranks #613 out of 958 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Jubilant Pharmova has a GF Score™ of 72/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Jubilant Pharmova's FCF Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Jubilant Pharmova ranks #613 out of 958 companies for FCF Margin %. This places Jubilant Pharmova in the lower half of its industry. The industry median FCF Margin % is 2.45. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.45, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Jubilant Pharmova and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jubilant Pharmova's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jubilant Pharmova stock overvalued right now?
Based on GuruFocus' analysis, Jubilant Pharmova (BOM:530019) is currently considered Fairly Valued. The stock's GF Value™ is ₹1,052.41, compared to a current price of ₹971.75 — trading 7.7% below its estimated fair value. The current FCF Margin % is 0.00%. Jubilant Pharmova's overall GF Score™ is 72/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Jubilant Pharmova (BOM:530019), the current FCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jubilant Pharmova (BOM:530019) Overvalued in 2026?
Based on GuruFocus' analysis, Jubilant Pharmova stock appears to be undervalued.
The current stock price of ₹971.75 is trading 7.7% below its estimated GF Value™ of ₹1,052.41.
GuruFocus considers Jubilant Pharmova to be Fairly Valued.
Key valuation signals for BOM:530019:
FCF Margin %: 0.00%
GF Value™: ₹1,052.41 vs. price of ₹971.75 (7.7% below fair value)
No single metric tells the full story. See the BOM:530019 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jubilant Pharmova Ltd is an integrated pharmaceutical company. The company operates in the following segments; Radiopharma; Allergy Immunotherapy; Contract Development and Manufacturing Organisation - Sterile Injectables; Generics; Contract Research, Development and Manufacturing Organisation; and Proprietary Novel Drugs. It generates maximum revenue from the Radiopharma segment which specializes in developing, manufacturing, commercializing, and distributing therapeutic agents in the nuclear medicine domain. Geographically, it derives a majority of its revenue from the Americas and Europe and the rest from India and the Rest of the world.
72GF Score
Get the complete analysis for BOM:530019
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:530019 has been successfully added to your 
